Conditions: Carcinoma, Non-Small Cell Lung
Keywords: Non-small cell lung cancer sunitinib erlotinib Phase 3
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 960
Healthy volunteers: no

Brief summary:
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: erlotinib intervention 2: sunitinib intervention 3: erlotinib intervention 4: placebo
Intervention descriptions: intervention 1: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity intervention 2: Sunitinib 37.5 mg daily by oral capsules in a continuous regimen intervention 3: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity intervention 4: Placebo daily by oral capsules in a continuous regimen

Protocol document: